ArticleActa parasitologica2026
Successful Management of Refractory toxoplasmosis-related Macular Neovascularization with Intravitreal Faricimab.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the therapeutic efficacy of intravitreal faricimab in a refractory case of macular neovascularization (MNV) secondary to toxoplasmic chorioretinitis.
methodsCase report.
resultsA 29-year-old woman presented with decreased vision in her right eye. She had been diagnosed with ocular toxoplasmosis four years earlier and subsequently developed secondary MNV, which was treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Previous intravitreal bevacizumab and aflibercept treatments resulted in minimal functional and anatomical improvement. On examination, best-corrected visual acuity was counting fingers at 2 m in the right eye and 1.0 in the left. Anterior segment findings were unremarkable. Fundus evaluation of the right eye revealed a subfoveal MNV with juxtafoveal hemorrhage and subretinal fluid, confirmed by optical coherence tomography (OCT) and OCT angiography. Due to persistent activation despite prior therapy, a single intravitreal faricimab injection was administered. At three-month post-faricimab injection, visual acuity improved to 0.2, and OCT demonstrated complete resolution of subretinal fluid with a marked decrease in central macular thickness.
conclusionIn the present case, intravitreal faricimab provided a remarkable anatomical and functional improvement in MNV secondary to toxoplasmic chorioretinitis that had been resistant to previous anti-VEGF treatments. Given its dual inhibition of VEGF-A and Angiopoetin-2, faricimab may offer an additional therapeutic advantage in managing inflammatory neovascular lesions.
Indexed as
Identifiers
41708575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.